ArticleDiscover oncology2026
Integrating single-cell and spatial transcriptomics with pan-cancer bulk sequencing identifies OSR2 as a multifaceted biomarker for prognosis and tumor immunity.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- WT1-AS acts as a tumor suppressor in cervical cancer via OSR2-mediated transcriptional activation.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOSR2 plays a key role in various physiological processes and cancer development. Although interest in OSR2’s role in cancer is increasing, its mechanisms and clinical importance are not fully understood. This study thoroughly examines OSR2 gene expression in different cancers and evaluates its potential as a prognostic marker and therapeutic target.
methodsA comprehensive pan-cancer analysis utilized single-cell RNA sequencing data from the CIDE database to examine OSR2 expression in various immune cells. Spatial transcriptomics from the CROST database explored OSR2’s spatial expression in renal carcinoma tissues. RNA sequencing data from the TCGA database assessed OSR2’s differential expression in 38 cancer types. The clinical significance of OSR2 was evaluated through its correlation with patient survival outcomes. Additionally, its impact on the tumor immune microenvironment was studied by analyzing associations with immunomodulatory factors, immune checkpoint molecules, and immune cell abundance.
resultsThe pan-cancer analysis revealed that OSR2 expression is often altered in various cancers. It is upregulated in 13 types, notably in gliomas like glioblastoma multiforme and low-grade glioma, and downregulated in 19 types, including kidney and bladder cancers. High OSR2 levels are linked to poor prognosis in several cancers and correlate with clinical factors such as age, gender, and tumor stage. Immunologically, OSR2 expression is positively associated with immunomodulatory and checkpoint genes in cancers like gliomas and colon cancer, but shows an antagonistic relationship with immune cell infiltration in prostate and pancreatic cancers.
conclusionThe findings suggest that OSR2 expression varies across cancer types and is linked to patient prognosis and changes in the tumor immune environment, making it a promising therapeutic target. Its role in tumor progression and immune interactions indicates its potential as a biomarker for cancer immunotherapy. Further research is needed to understand OSR2’s molecular mechanisms in cancer and to validate its use in immunotherapy.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.